LPCN

Conviction 0HealthcareScan · Thu, Oct 8, 2026

Lipocine Inc. (LPCN) closed at $1.93 (-12.27%) on Oct 8, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 37, RS Rating 85, -82.9% from its 52-week high, -75.9% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.

LPCN$1.93-12.27%

ResistanceSupportVol 14

Vol MA14 7.66M

Jul 13Jul 29Aug 17Sep 2Sep 22Oct 8

Lipocine Inc.PHARMACEUTICAL PREPARATIONSwww.lipocine.com ↗

Price1.93

Change-12.27%

Gap-7.27%

Rel volume0.18×

Avg volume5.38M

Avg $ vol11.81M

SMA 202.14

SMA 502.16

SMA 2004.37

Price vs 50-10.54%

Price vs 200-55.83%

MA stackbearish

50/200 cross—

Supertrenddown · 2.39

RSI (14)37

MACD hist-0.01

MACD cross—

Stoch %K / %D3 / 14

ADX (14)21

+DI / −DI43 / 13

RSI divergence—

MACD divergenceBullish

ATR %9.57%

ADR %6.98%

52w high11.26

52w low1.93

From 52w high-82.86%

Above 52w low+0.00%

New 52w highNo

SqueezeOn · 3d

Bollinger width14.79%

%B-0.17

Donchian pos3.17%

Donchian high3.15

Donchian low1.89

AVWAP (52w high)2.70

vs AVWAP high-28.41%

AVWAP (52w low)2.40

vs AVWAP low-19.68%

OBV trendUp

Chaikin MF (20)-0.75

Today vs 20d0.18×

Avg vol (14d)7.66M

Avg vol (20d)5.38M

Avg $ vol (20d)11.81M

Market cap15.91M

RS Rating85 / 99

RS 3m (vs SPY)-22.42%

RS 6m (vs SPY)-21.47%

RS line new highNo

Trend template0/8

Technical rank16.0

1 week-6.76%

1 month-14.22%

3 months-19.92%

6 months-7.66%

1 year-40.06%

YTD-75.88%

P/E-1.65

P/B0.73

P/S31.82

P/FCF-1.62

EPS-1.69

Div yield—

ROE-44.23%

ROA-40.39%

Debt/Eq0.13

Current11.48

EV/EBITDA-1.34

Gross margin—

Net margin—

Rev growth-96.90%

EPS growth—

Price target5.00

Target upside159.07%

Analyst ratingBuy

Institutional38.84%

Ent. value13.86M

Revenue54.99K

Net income-2.62M

Gross profit—

Free cash flow-9.85M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out—

Employees14

ListedTue, Jun 5, 2012

Free float5.19M

Float %93.4%

Short interest100.99K

Days to cover3.0d

Short volume52.8%

Squeeze score27 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.32 vs −$0.47

Last surprise+31.9% beat

Setup gradeD

Conviction0 / 100

Pattern quality—

Tech rank16.0 / 100

Group rank14 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance2.40

Support2.04

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in LPCN

All disclosures →

No recent disclosed trades by Congress in LPCN. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in LPCN

Insider	Side	Shares	Value	Traded	Filed
Grissinger Michael Director · Stock Option (Right to Buy) · 2026-08-03	Grant	2K	$4K	2026-08-03	2026-08-07
Patel Mahesh V. Chief Executive Officer · Stock Option (Right to Buy) · 2026-06-29	Grant	52.78K	$131K	2026-06-29	2026-06-30
Jene Jill M. Director · Stock Option (Right to Buy) · 2026-06-03	Grant	1.76K	$4K	2026-06-03	2026-06-04
Higuchi John W. Director · Common Stock (Right to Buy) · 2026-06-03	Grant	1.76K	$4K	2026-06-03	2026-06-04
Ono Richard Dana Director · Common Stock (Right to Buy) · 2026-06-03	Grant	1.76K	$4K	2026-06-03	2026-06-04

SEC filings

EDGAR filings in LPCN · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.

LPCN

Recent news

Get daily signals & real-time alerts.